|Title||The combined expression of solute carriers is associated with a poor prognosis in highly proliferative ER+ breast cancer|
|Authors||El Ansari, R., Craze, M.L., Alfarsi, L., Soria, D., Diez-Rodriguez, M., Nolan, C.C., Ellis, I.O., Rakha, E.A. and Green, A.R.|
Purpose: Breast cancer (BC) is a heterogeneous disease characterised by variant biology, metabolic activity, and patient outcome. Glutamine availability for growth and progression of BC is important in several BC subtypes. This study aimed to evaluate the biological and prognostic role of the combined expression of key glutamine transporters, SLC1A5, SLC7A5 and SLC3A2 in BC with emphasis on the intrinsic molecular subtypes.
|Keywords||SLC1A5, SLC7A5, SLC3A2, clusters, breast cancer, prognosis|
|Journal||Breast Cancer Research and Treatment|
|Digital Object Identifier (DOI)||doi:10.1007/s10549-018-05111-w|
|Published online||22 Jan 2019|